Ldb Case Study

Many studies were conducted on coronary artery disease (CAD) because it is the leading cause of mortality and premature disability so studies investigated those at risk of coronary atherosclerosis aiming to provide early treatment (Kolovou et al., 2005), (Akhabue et al., 2014).

In 2008 to 2009, it is estimated over $7,000 million, approximately 12% of healthcare expenditure, was spent on CVD care (Australian Institute of Health and Welfare 2014). Many CVD patients survive the acute phase by utilising advanced pharmacological therapies and interventional cardiovascular technology, but they have to live with a chronic condition for the rest of their lives. According to the National Heart Foundation of Australia (2010) CVD is a preventable disease and many of the risk factors can be managed through lifestyle modification and preventive treatment. However, adults with limited or marginal health literacy may often misinterpret the health related information, resulting in ineffective communication with the healthcare professionals,

This guidance can be used alongside the NHS Health Check programme, the national vascular risk assessment and management programme for those aged 40–74. This is an integrated approach to identifying and preventing four diseases: diabetes, cardiovascular disease, stroke and kidney disease (NHS Health Check Programme, 2009). The programme is being rolled out throughout England. The aim is to ensure everyone aged 40–74 who has not already been diagnosed with one of these conditions is offered a risk assessment and given advice and support to help them reduce and manage that risk.

Currently, Heart disease is the leading cause of death among women in the United States (Haskell et al., 2014). In the 2016 Update of the Heart Disease and Stroke Statistics report from the American Heart Association, women, in general, have a 32% prevalence rate for LDL issues vs. 31% for men. Likewise, in older women vs older men, the prevalence for hypertension rates for women were 57% vs. 54% in men (Mozaffarian et al., 2016). Within the VA, there is an even bigger gap for management of LDL’s and heart disease. 79.47% of women vs. 88.89% of men have LDL levels within the normal limits. Similarly, 79.34% of women vs. 85.67% of men with diabetes had an LDL within normal limits (Whitehead et al., 2014). Both high LDL and hypertension are proven risk factors for heart disease and stroke. When paired with diabetes, risk of peripheral artery disease, heart failure, and irregular heartbeat can also be factors (Mozaffarian et al., 2016).

The 2016 USPSTF guidelines for the prevention of CVD are highly credible and demonstrate a thorough evaluation of credible evidence and provided understandable and easily applied practice recommendations. The guidelines can be readily applied to a variety of health care settings and providers to promote the long-term health of their patients. Recent updates in 2016 ensure that the most evidence-based information has been applied in their formulation. Use of these guidelines will help reduce the risk of CVD while minimizing complications attributed to the

Current guidelines state that ezetimibe,is considered the best alternative for LDL reduction and tolerability in statin-intolerant patients and considered an adjuvant in this trial. The primary end point was percentage change from baseline to week 12 in LDL cholesterol. Other end points included measures of safety and tolerability of different doses of AMG145 and AMG145 plus ezetimibe. Other objectives included assessment of the safety and tolerability of 3 different doses of AMG145 and AMG145 plus ezetimibe compared with placebo plus ezetimibe. One hundred sixty patients were randomized into 5 groups, to take AMG 145 as monotherapy once a month at 280mg, 320mg and 420mg, to take AMG 145 420mg once a month with ezetimibe 10mg daily or placebo once a month with ezetimibe 10mg daily. At week 12 the AMG 145 groups had a percent change of blood levels of LDL from baseline from -40.8 % to -50.7 % dose ascending monotherapy and -63.0% with combination with ezetimibe versus -14.8% with combination of placebo and ezetimibe. Reduction in total cholesterol percentwise was from -29.8 % to -37.7 % dose ascending monotherapy and -43.3% with combination with ezetimibe versus -10.7% with combination of placebo and ezetimibe. The overall incidence of all adverse effects was similar among patients receiving

This 54 year ld AAM. Patient has a history o fDM, HTN, and hyperlipidemia. Patient's current medications are Glipizide 10 mg BID, ASA 81 mg QD, Triamtereine /HCTZ 75/50 mg, Pravastatin 40 mg QHS, and lorsatan 300 mg QD. Patient states he is taking all mthe medications as prescribed, and he thought he was doing fine. Patient states no one in the Federal Prison System had checked his A1C in several years. The patient's A1C today is greather than 14 %. Patient denies buller vision, headache, chest pain, SOB, N/V/D, or fever. The patient denies decreased sensation of his feet, increased thirst or urination. Patient denies any depressive moods. The patient is here with his wife and had a long disussion with the plan of care for his DM, HTN, and

D.B was a restaurant manager who left the business in (2005) to attend nursing school at the University of South Florida (USF) where she obtained her BSN degree. While working in the Coronary Intensive Care Unit (CICU), she went to the University of Tampa for the ARNP but did not like it. In 2013 she went on to pursue a Master’s of Science degree in Healthcare Informatics (HCI) at the University of Central Florida (UCF). D.B is currently working as a per-diem for a prestigious private hospital in South Florida where she is currently a Super User/User Support for the Epic Systems. She also work for a nursing travel Agency and travelled throughout the country working as an Epic Super User or User Support for various hospitals during “go live-live implementation.” Although she obtained her MS-HCI, surprisingly she is not working in this job

In the beginning of the CDBS, it was estimated up to 3.1 million eligible children aged from 2 to 17 years will access basic dental services under this means-tested scheme (Department of Health, Australian Government 2016). Among those eligible children, approximately 677,578 children in 2014 and 567,030 children in 2015 enrolled which is around 22% in 2014 and 18% in 2015 which showed 16.32% decline between those years. This study also found that SA has the largest proportion of eligible children who enrolled in CDBS and NT was the opposite. The highest proportion of eligible children is in TAS. However, children participation in the scheme in this state is only 6,48%

Mary is a 74-year-old female who suffers from mixed hyperlipidemia (E78.2), along with atherosclerotic heart disease, multiple aortocoronary bypass graft, and hypertension. Mary’s most recent lab results revealed triglycerides 115, HDL cholesterol 44 and LDL cholesterol 116, and total cholesterol 191. Mary has tried and failed various treatments including zetia and Lipitor, with her cholesterol level sub-optimally controlled. Mary’s LDL remains elevated, uncontrolled, and still, did not meet the criteria of being less than 70 in the presence of known cardiovascular disease. Repatha is Mary’s best treatment option at this time. Although, Repatha is not on your formulary, I am requesting an exception for coverage. Without this treatment,

As far as the NLRB is concerned this is a 8(a) (5) unilateral change allegation that without a doubt would be Collyerize based on the pending grievance and arbitration. The basis for the grievance is that the contract incorporates the State Law standard which prohibits by-weekly pay absent an agreement and the Union contends there was no agreement. The employer on the other hand contends that there was an agreement as evidence by the change in contractual language allowing a change in the “pay date.” In support of the affidavit you are going to have to the emails back and forth between the Union and the company announcing the change in the payroll arrangement and the Union’s response.

Increased cholesterol levels, particularly low-density lipoprotein cholesterol (LDL-C), is one of the most potent CV risk factors. Epidemiological data show a continuous log-linear relationship between serum cholesterol levels and risk of CHD (Grundy et al. 2004). There are inconsistent reports of increased cholesterol levels in PD patients (Hayward et al. 1989; Tancer et al. 1990; Bajwa et al. 1992; Agargun et al. 1996; Shiori et al. 2000; Peter et al.

Atherosclerosis is a disease in which fatty materials and plaque buildup on the inner lining of arteries. Arteries are blood vessels which carry rich blood to the heart and throughout the body. They’re lined by the endothelium, a thin layer of cells. The endothelium keeps blood flowing by keeping the inside of arteries smooth. However, when Atherosclerosis starts due to high blood pressure, smoking, or high cholesterol, it damages the endothelium. Atherosclerosis tends to happen throughout the body and arises when people grow older. This disease is mainly due to the deposition of fatty materials i.e., cholesterol, calcium and other substances found in the blood. The buildup of fat then hardens causing narrowing of the arteries. This

One source of great mortality and morbidity in Europe and North America is the cardiovascular disease, Atherosclerosis. It is recognized as a chronic inflammatory disease of the intermediate and large arteries characterized by the thickening of the arterial wall and is the primary cause of coronary and cerebrovascular heart disease (Wilson, 2005). It accounts for 4.35 million deaths in Europe and 35% death in the UK each year. Mortality rate are generally higher in men than pre-menopausal woman. Past the menopause, a woman’s risk is similar to a man’s (George and Johnston, 2010). Clinical trials have confirmed that lipid accumulation, endothelial dysfunction, cell proliferation, inflammation matrix alteration and foam cell formation are

Annual testing for abnormalities in fasting serum cholesterol, triglyceride, HDL cholesterol, and calculated LDL cholesterol levels (ADA, 2008)